NCT05243823View on ClinicalTrials.gov

Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy

CompletedOBSERVATIONAL
Enrollment

500,000

Participants

Timeline

Start Date

January 15, 2022

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Postmenopausal Vaginal Atrophy
Interventions
DRUG

Vagifem®

According to local clinical practice - independent of inclusion in this study

DRUG

Non-Vagifem® LDVE, Estradiol

According to local clinical practice - independent of inclusion in this study

Trial Locations (1)

Unknown

Novo Nordisk Investigational Site, Soeborg

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT05243823 - Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy | Biotech Hunter | Biotech Hunter